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Neospora caninum is considered to be the main cause of bovine abortion in Europe and the USA, leading to
considerable ﬁnancial impact. Losses are caused directly by abortions or indirectly through breeding of
calves with impaired viability. Due to the lack of effective chemotherapy against bovine neosporosis, there
is a need to develop new anti-protozoal compounds, which would either eliminate the parasite or avoid its
transmission. In order to identify compounds of interest, the in vitro activities of 41 di-cationic pentami-
dine derivatives were studied employing a transgenic N. caninum clone expressing beta-galactosidase as
a reporter gene. The arylimidamide DB745, previously shown to be highly active against Leishmania dono-
vani in vitro and in vivo, appeared as the most promising compound, with an IC50 of 80 nM in 3-day growth
assays and severely affecting both host cell invasion as well as intracellular proliferation. TEM of intracel-
lular tachyzoites identiﬁed distinct alterations related to the nucleolus and the nuclear and cellular mem-
brane. Long-term growth assays showed that DB745 acted parasiticidal upon the Nc-Liv isolate, but not
against the Nc-1 isolate of N. caninum. In vivo studies in N. caninum (Nc-1 isolate) infected mice showed
that daily intraperitoneal application of DB745 for a period of 14 days resulted in a decreased number of
clinically affected animals, and lower cerebral parasite burdens in DB745-treated mice compared to
non-treated mice. These results illustrate the potential of dicationic arylimidamides for the treatment of
N. caninum infections.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction reagents are developed (Häsler et al., 2006a,b; Monney et al.,The obligatory intracellular apicomplexan parasite Neospora
caninum represents a major cause of stillbirth, abortion, or birth
of weak calves all around the planet, with considerable economic
implications. Besides abortion, other factors such as reduced milk
yield, premature culling and reduced post-weaning weight gain
in beef calves have been published, although conﬂicting results
regarding the importance of milk yield and weight gain have been
reported (Dubey and Schares, 2011). Due to the large economic im-
pact of neosporosis especially in cattle, considerable efforts have
been put into research on accurate diagnosis, prevention and treat-
ment of N. caninum infection (Dubey et al., 2007). Vaccination and
chemotherapy have been identiﬁed as economically promising op-
tions for intervention, provided that suitable targets and effectivePublished by Elsevier Ltd.
: +41 31 631 2477.
.ch (A. Hemphill).
are designated ﬁrst authors.
Open ac2011a).
Infection by N. caninum in herbivores such as cattle occurs in
two ways: on one hand through oral uptake of oocysts containing
infective sporozoites, which are shed by canine deﬁnitive hosts and
subsequently disseminate and differentiate into the proliferative
tachyzoite stage, or through transplacental infection by rapidly
proliferating tachyzoites from dam to the fetus. In an immuno-
competent host, the proliferative tachyzoite stage is replaced by
the quiescent bradyzoites at the onset of the host immune re-
sponse, and bradyzoites then form tissue cysts predominantly lo-
cated in the central nervous system (CNS) and muscle tissue,
where they do not cause apparent immunopathology and can per-
sist for many years, up to a lifetime (Hemphill et al., 2006; Dubey
et al., 2007). During pregnancy, and associated immunomodula-
tion, recrudescence can occur, followed by bradyzoite-to-tachyzo-
ite interconversion, and subsequent endogenous trans-placental
infection represents the main source of neosporosis in cattle.
The chemotherapeutical options for the treatment of N. caninum
infections are limited. The main problem lies in the fact that ancess under CC BY-NC-ND license.
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and also affect the encysted bradyzoites stage in the chronic phase
of infection. In addition, cost-effectiveness and potential residues
in meat or milk are important issues. In the past, a wide range of
compounds were investigated in vitro, such as lasalocid, monensin,
pirithrexim, pyrimethamine, clindamycin, robenidine and trimeth-
oprim (Lindsay et al., 1994), artemisinin (Kim et al., 2002), depude-
cin (Kwon et al., 2003), toltrazuril, ponazuril (Darius et al., 2004),
nitazoxanide and other nitro-and bromo-thiazolides (Esposito
et al., 2005, 2007a,b), alcoholic herbal extracts (Youn et al.,
2004), di-cationic arylimidamides (Leepin et al., 2008), and mil-
tefosine (Debache and Hemphill, 2012). Only few drugs have been
used in vivo. In clinical settings, clindamycin, potentiated sulph-
onamides and pyrimethamine, drugs that are in use the treatment
of toxoplasmosis caused by the closely related Toxoplasma gondii,
were successful in eliminating clinical signs in 10 of 27 cases of ca-
nine neosporosis (Barber and Trees, 1996). Other compounds have
been experimentally evaluated in small animal models, including
sulfadiazine and amprolium in mice, which did not eliminate the
parasite (Lindsay and Dubey, 1990). Inclusion of toltrazuril into
the drinking water eliminated parasites in the central nervous sys-
tem of C57Bl/6 mice, but cell-mediated immunity was required to
achieve its full efﬁcacy (Ammann et al., 2004). Toltrazuril treat-
ment also controlled dia-placental N. caninum transmission in
experimentally infected pregnant mice (Gottstein et al., 2005; Stro-
hbusch et al., 2009). In addition, studies on prophylactic toltrazuril
administration in newborn calves suggested that this treatment re-
gime could exhibit a certain degree of protective efﬁcacy (Härdi
et al., 2006; Kritzner et al., 2002). Intragastric application of mil-
tefosine was shown to be effective in reducing clinical signs of neo-
sporosis in Balb/c mice and resulted in reduced cerebral parasite
burden (Debache and Hemphill, 2012).
Pentamidine and its analogues represent a class of broad-spec-
trum antimicrobial compounds, with activities against a wide
range of intracellular and extracellular protozoan parasites (Buck-
ner and Navabi, 2010; Soeiro et al., 2005; Wilson et al., 2008). Since
its discovery, pentamidine has been successfully applied to treat
African trypanosomiasis, leishmaniasis, and malaria in humans,
and the pentamidine-derivative diminazene aceturate is com-
monly used for trypanosome chemotherapy in livestock (Werbo-
vetz, 2006). More recently, novel analogues, known as
arylimidamides, with more favorable pharmacokinetic proﬁles, im-
proved bioavailability and lower host toxicity were shown to be
effective against Leishmania donovani, Trypanosoma cruzi, T. gondii
and Besnoitia besnoiti (Batista et al., 2010a,b; Cortes et al., 2011;
De Souza et al., 2011; Kropf et al., 2012; Wang et al., 2010). Earlier
reports had demonstrated good in vitro efﬁcacy of DB750 and re-
lated compounds against N. caninum, with IC50 levels of at submi-
cromolar concentrations ranging between 0.16 and 0.66 lM,
indicating the potential of these di-cationic compounds for chemo-
therapeutical purposes. Debache et al. (2011) showed that treat-
ment of N. caninum-infected mice with the diamidine DB750 led
to a signiﬁcant reduction of clinical signs of disease and cerebral
parasite burden, indicating that this compound could cross the
blood–brain barrier. Here, we further explored the in vitro and
in vivo characteristics of a set of related di-cationic compounds,
and identiﬁed the arylimidamide DB745 as an interesting candi-
date for further development to treat N. caninum infections.2. Materials and methods
Unless otherwise stated, all tissue culturemediawere purchased
from Gibco-BRL (Zurich, Switzerland) and biochemical reagents
were from Sigma (St. Louis, MO). The di-cationic compounds used
in this study were synthesized at the Department of Chemistryand Center for Biotechnology and Drug Design, Georgia State Uni-
versity, USA, or at the Department of Chemistry and Physics, Augus-
ta State University, USA. They were kept as dry powder or as stock
solutions of 1 mg/ml in dimethyl sulfoxide and were stored at
20 C.
2.1. Cell culture and parasite puriﬁcation
Vero cells were maintained in RPMI 1640 medium supple-
mented with 5% foetal calf serum (FCS), 2 mM L-glutamine, 50 U
of penicillin/ml, and 50 lg of streptomycin/ml at 37 C with 5%
CO2 in tissue culture ﬂasks and were trypsinized 3 times a week.
Human foreskin ﬁbroblasts (HFF) were maintained in Dulbecco’s
modiﬁed Eagles’s medium (DMEM) with 10% FCS, 50 U of penicil-
lin/ml, and 50 lg of streptomycin/ml at 37 C with 5% CO2 in tissue
culture ﬂasks. Cultures were trypsinized once a week. Transgenic
N. caninum Nc-1 (Nc-1 isolate) expressing beta-galactosidase (N.
caninum-beta-Gal), wildtype N. caninum Nc-1 and N. caninum Nc-
Liv (Liverpool-isolate) were cultured in Vero cells as described ear-
lier (Hemphill et al., 1996). Intracellular parasites were harvested
by trypsinization of infected Vero Cells, followed by repeated pas-
sages through a 25-gauge needle at 4 C, and separation from cell
debris on a Sephadex-G25 column (Hemphill et al., 1996). Puriﬁed
tachyzoites were used to infect HFF monolayers as described
below.
2.2. In vitro drug assays employing N. caninum-beta-Gal
Drugs were tested for activity against N. caninum-beta-Gal tach-
yzoites in 3 day growth assays employing ﬂat-bottomed 96 well
tissue culture plates (Sarstedt, Sevelen, Switzerland), essentially
as described for T. gondii expressing beta-galactosidase (McFadden
et al., 1997; Kropf et al., 2012). 5  103 HFF/well were cultured in
phenol-red free DMEM medium at 37 C and 5% CO2 until they
had grown to conﬂuency. Prior to drug treatment, the old medium
was removed and 100 ll of phenol-red free DMEM medium con-
taining 1  103 freshly harvested N. caninum-beta-Gal tachyzoites
were distributed per well and placed at 37 C/5% CO2. After 1 h,
the drugs were added in desired amounts (1 lM for initial screen-
ing and 1 lM in 1:2 dilutions down to 0.0625 lM for IC50 determi-
nation) in 100 ll phenol-red free DMEM medium. Controls
included non-drug-treated infected HFF monolayers and non-in-
fected HFF. Eight wells were used per experimental assay, and 8
wells remained untreated in order to serve as a positive control.
The plates were then incubated again at 37 C and 5% CO2. After
72 h, the plates were centrifuged at 50g for 5 min and the medium
was removed. Subsequently, 90 ll of PBS containing 0.05% of Tri-
ton X-100 were added per well and air bubbles were removed with
a 25 G needle. The plate was then ﬁrst test-read in a 96-well plate
reader (VersaMax multiplate reader, Bucher Biotec, Basel, Switzer-
land). Subsequently, 10 ll of 5 mM chlorophenol red-b-D-galacto-
pyranoside (CPRG; Roche Diagnostics, Rotkreuz, Switzerland)
solved in PBS were added per well. The absorption shift was mea-
sured at (A570) at various time points. The initial velocity (DA570/
min) was proportional to the number of tachyzoites. IC50 values
were calculated after the logit-log-transformation of the relative
growth (RG; control = 1) according to the formula ln[(RG/
(1  RG)] = a  ln(drug concentration) + b and subsequent regres-
sion analysis by the corresponding software tool contained in the
Excel software package (Microsoft, Seattle, WA, USA).
2.3. Assessments of host cell toxicity
Flat bottomed 96 well plates (Sarstedt) were seeded with
5  103 HFF cells/well in phenol-red free DMEMmedium and incu-
bated at 37 C and 5% CO2 until they had grown to conﬂuence.
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experimental assay) were added in desired amounts. One row of 8
wells remained untreated as a blank and another row of 8 wells
was treated with 0.5% Triton X-100 as a positive control. The 96-
well plates were incubated at 37 C and 5% CO2 for 72 h. After
72 h, 10 ll of 20 resazurin were added per well and the ﬂuores-
cence (A590) was measured at various time points using the Wallac
Victor2 1420 multilabel counter (Perkin Elmer, Schwerzenbach,
Switzerland). Resazurin is a blue indicator dye that is non toxic
and nonﬂuorescent. Living cells however gradually convert it to
resoruﬁn, which releases very strong red ﬂuorescence. Therefore,
the cells’ metabolic activity can be directly evaluated by measuring
the generated amount of ﬂuorescence because it is directly propor-
tional to the number of viable cells.
2.4. Pretreatment of N. caninum-beta-Gal tachyzoites with DB745
prior to invasion of HFF
Flat-bottomed 96-well tissue culture plates (Sarstedt) were
seeded with 5  103 HFF/well and these were grown to conﬂuency
in phenol-red-free DMEM medium at 37 C and 5% CO2. Freshly
puriﬁed N. caninum-beta-Gal tachyzoites were then pre-treated
with 1 lM DB745 at 37 C for 15 min, 30 min, 1 h and 2 h, respec-
tively, or were not treated at all. Parasites were then added to the
HFF monolayers at 1  103 parasites/well for 1 h at 37 C/5% CO2,
then the medium and non-adherent parasites were removed, and
the wells were washed once with 200 ll medium. Finally, 200 ll
of fresh mediumwithout 1 lMDB745 was added. The infected cul-
tures were maintained at 37 C/5% CO2 for 3 days, and relative
infection intensities were quantiﬁed by adding the substrate and
measuring A570 as described above. All assays were done in 8 wells
in parallel, and this experiment was repeated three times with
essentially identical results.
2.5. Pre-treatment of HFF monolayers with DB745 prior to infection
with N. caninum-beta-Gal tachyzoites
Assays were carried out in ﬂat-bottomed 96-well plates seeded
with 5  103 HFF/well and grown to conﬂuency in phenol-red free
DMEM medium. Half the monolayers were pre-treated with 1 lM
DB745 in fresh medium over night, the other half received DMEM
without compound. Subsequently the medium was removed and
the monolayers were washed twice with 200 ll DMEM before
infecting them with 1  103 parasites/well suspended in medium
without DB750. Controls received 1 lM DB745 at 1 h post-infec-
tion as described above. Cultures were maintained for 72 h at
37 C/5% CO2 and relative parasite proliferation was measured by
spectrophotometry (A570). All assays were done in 8 wells in paral-
lel, and the experiment was repeated three times with essentially
identical results.
2.6. Transmission electron microscopy (TEM)
HFF monolayers grown in 25 cm2 tissue culture ﬂasks were in-
fected with N. caninum Nc-1 tachyzoites. At 2 days post-infection,
treatments with 1 lM DB745 were initiated. Samples were col-
lected 24, 48 and 72 h later, respectively, by removing the medium
and washing the monolayers twice with 100 mM sodium cacodyl-
ate buffer (pH 7.2). Fixation was carried out in 100 mM sodium
cacodylate buffer pH 7.3 containing 2.5% glutaraldehyde for 2 h
at room temperature. Then specimens were washed twice with
100 mM cacodylate buffer, were scraped off with a rubber police-
man, and centrifuged at 100g for 10 min at 4 C. Postﬁxation was
done in cacodylate buffer containing 2% OsO4 at 22 C for 2 h. Sub-
sequently, specimens were washed in water, and pre-stained in 1%
uranyl acetate in water for 30 min, followed by an extensive washin water. The samples were dehydrated in a graded series of etha-
nol (30%, 50%, 70%, 90%, and 100%), and were embedded in Epon
820 epoxy resin as described in Kropf et al. (2012). The resin was
polymerized at 65 C for 24 h. Ultrathin sections (80 nm) were
cut on a Reichert and Jung ultramicrotome and were loaded onto
300-mesh copper grids (Plano GmbH, Marburg, Germany), and
stained with uranyle acetate and lead citrate (Hemphill et al.,
2004). Grids were viewed on a Philips 400 transmission electron
microscope (TEM) operating at 80 kV.
2.7. In vitro adaptation of N. caninum Nc-1 and N. caninum Nc-Liv to
increased concentrations of DB745 and assessment of parasiticidal
activity
Conﬂuent HFF monolayers grown in T25 tissue culture ﬂask
(Sarstedt) were infected with N. caninum (Nc-1 and Nc-Liv, respec-
tively) and were exposed to successively increasing DB745 drug
concentrations over time, starting with 0.02 lM, and further ele-
vated stepwise every 3–4 days by 0.02 lM. Cultureswere evaluated
light microscopically on a daily basis, and if no further proliferation
was noted, the drug concentration was not increased. Every 6–
9 days, parasites were passaged onto fresh HFF by trypsinization
of infected cultures, washing them in PBS, and adding them to fresh
monolayers previously grown overnight. The maximum DB745
concentration used was 0.3 lM for Nc-1 and 0.22 lM for Nc-Liv.
Experiments were terminated on day 111 of drug treatment.
2.8. In vivo experiment 1: DB745-treatment of Balb/c mice
experimentally infected with N. caninum Nc-1 and drug application
starting prior to infection
Thirty female Balb/c mice between 8 and 9 weeks of age were
purchased from Charles River Laboratories (Sulzheim, Germany)
and were maintained in a common room under controlled temper-
ature and a 14 h dark/10 h light cycle according to the standards
set up by the animal welfare legislation of the Swiss Veterinary Of-
ﬁce. At day zero, mice were randomly caged into three experimen-
tal groups of 10 mice as outlined in Table 2. Enzyme-linked
immunosorbent assay (ELISA) was carried out to ensure that mice
were serologically Neospora-negative (Debache et al., 2010). Mice
received either DB745 or DB750 2 mg/kg/day; (Debache et al.,
2011) as suspensions in 0.5% carboxymethyle-cellulose in water
(CMC) by intraperitoneal injection of a volume of 100 ll. The pla-
cebo group obtained the corresponding amount of the solvent only
(see Table 2). The treatments were performed on a daily basis,
starting at day 1. On day 3, all mice were infected by intraperito-
neal injection of 2  106 freshly puriﬁed N. caninum (Nc-1) tach-
yzoites in medium. If not indicated otherwise, treatments
continued until day 18 (day 14 post-infection), after which the
mice were sacriﬁced by CO2-euthanasia. Mice exhibiting clinical
signs of neosporosis (rufﬂed coat, apathy, hind limb paralysis) were
euthanized at the onset of these clinical signs. Blood was taken by
heart puncture for serological analysis and from each animal the
brain was recovered, and was processed for DNA-extraction
(Debache et al., 2010; Monney et al., 2011b).
2.9. In vivo experiment 2: DB745-treatment of Balb/c mice with drug
application starting 14 days after infection with N. caninum Nc-1
tachyzoites
Forty female Balb/c mice were purchased and housed as de-
scribed above. 9 mice remained uninfected, and on day 1 the
remaining 31 mice were infected by intraperitoneal injection of
2  106 N. caninum (Nc-1) tachyzoites. Four of these mice exhibited
clinical signs during the ﬁrst 2 weeks and were euthanized. On day
14 post-infection, the remaining 27 mice were allocated into
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toneal injections of DB745 (2.5 mg/kg/day) for 14 days as above.
The second group (n = 9) received intraperitoneal injections of
DB745 (7.5 mg/kg/day) for 14 days, and the third group (n = 9) re-
ceived DB745 (7.5 mg/kg/day) for 14 days, but was not infected.
The fourth group (n = 8) was treated with solvent only. On day
28, all mice were sacriﬁced by CO2-euthanasia and brain and lung
tissues were collected as above.
2.10. DNA extraction and assessment of cerebral parasite burden by
real time PCR
DNA puriﬁcation from in vitro cell culture and cerebral tissues
was performed emoploying the DNeasy Blood & Tissue Kit (Qia-
gen, Basel, Switzerland) according to the standard protocol suitable
for animal tissues. The DNA concentrations in all samples were
determined by UV spectrophotometry (NanoDrop™, Thermo Sci-
entiﬁc, Delaware, USA) and adjusted to 100 ng/ll with sterile
DNAse free water. The assessments of N. caninum tachyzoite loads
were performed using the Rotor-Gene 6000 real-time PCR machine
(Corbett Research, Qiagen). The parasite counts were calculated by
interpolation from a standard curve with DNA equivalents from
1000, 100 and 10 parasites included in each run (Debache et al.,
2010; Monney et al., 2011b).
2.11. Data analysis
Statistical analysis to test for differences among all independent
groups was performed using a one way (ANOVA) analysis of vari-
ance test (ANOVA). The ANOVA test was applied in combination
with Tukey’s HSD (Honestly Signiﬁcant Difference) test, P values
<0.01 and <0.05 were considered statistically highly signiﬁcant
and signiﬁcant, respectively. Survival analysis in the in vivo exper-
iment 2 was performed according to Kaplan–Meier method and the
treatment group was compared with the corresponding placebo
group by Cox regression, employing the open-source software
package R (2009). Cerebral parasite burdens and viable parasite
load in different treatment and placebo groups were statistically
assessed by Kruskal–Wallis multiple comparison, followed by Dun-
can’s multiple range test to compare between two particular
groups (P < 0.05). Monitoring of mouse weights were statistically
evaluated by Ducan’s multiple range tests and a value of P < 0.05
was taken as statistically signiﬁcant. All analyses of variances em-
ployed the NCSS Quick Start 2001 software.3. Results
3.1. In vitro screening of di-cationic pentamidine derivatives against N.
caninum tachyzoites
N. caninum-beta-Gal tachyzoites were used for screening of a
series of selected di-cationic pentamidine derivatives (Wang
et al., 2010; Kropf et al., 2012), including 10 di-arylimidamides
(DB666, DB667, DB702, DB710, DB745, DB780, DB786, DB865,
DB891, DB930), 6 diamidines (DB1282, DB1341, DB1362,
DB1407, DB1450, DB1479), 15 newly generated mono-arylimida-
mides (DB1980, DB1996, DB1997, DB2001, DB2002, DB2006,
DB2007, DB2018, DB2036, DB2045, DB2048, DB2074, DB2079,
DB2081, DB2083), and 10 di-guanidino analogues (DB856,
DB857, DB859, DB866, DB869, DB872, DB944, DB1127, DB2086,
DB2091) all at an initial concentration of 1 lM. Evaluation of
beta-galactosidase activity after 72 h of exposure to these drugs re-
vealed that the mono-arylimidamides tested did not show any ad-
verse effects on N. caninum proliferation nor on host cells, while
the di-guanidino compounds exhibited more host cell toxicityand no or only very little anti-parasitic activities (data not shown).
The highest proliferation-inhibitory effect and lowest host-cell tox-
icity was recorded for the di-arylimidamide DB745, which is clo-
sely related to the compound DB750 previously identiﬁed by
Leepin et al. (2008) (Fig. 1A and C). Dose–response studies on
DB745 resulted in an IC50 of 0.08 lM (±0.012), a value that was de-
rived from three independent experiments, which was half of what
was previously reported for DB750. A virtually complete inhibition
of tachyzoite proliferation was noted at 0.5 lM (Fig. 1A). Assess-
ment of host cell toxicity by light microscopical inspection of unin-
fected HFF monolayers exposed to increasing concentrations of
DB745 (0, 0.5, 1, 2 or 3 lM) for 2 times 3 days revealed that treat-
ments with 0.5–2 lM did not result in visible adverse reactions in
HFF monolayers, while at 3 lM a 50% reduction in viable HFF was
observed (data not shown). In addition, metabolic activities of HFF
were measured by Alamar-blue assay after treatments with
increasing DB745 concentrations (Fig. 1B), showing that DB745
inﬂuenced host cell viability in a dose dependent manner. At low
concentrations (1.25 and 0.625 lM) the HFF metabolic activity
was reduced by 15% compared to the untreated control. Concentra-
tions over 5 lM impaired the viability of the host cells by 70–90%.
Altogether, these ﬁndings render DB745 a promising candidate for
additional experimental testing both in vitro and in vivo.
3.2. DB745-treatment of extracellular N. caninum-beta-Gal
tachyzoites affected host cell invasion and proliferation of parasites
Further experiments aimed to investigate the effects of DB745
treatment on tachyzoite invasion and re-growth. N. caninum-
beta-Gal tachyzoites were pre-incubated at 37 C in the presence
or absence of DB745 (1 lM) for several durations. They were then
added to HFF monolayers for infection and the medium was re-
moved after 1 h, and replaced with fresh medium without com-
pound. After culture of 3 days, the number of viable parasites
was evaluated. As can be seen in Fig. 2A, the presence of DB745
during the invasion process itself (0 min pre-treatment time and
exposure to DB745 only during invasion) already had a profound
inhibitory effect. This suggested that DB745 acted very efﬁciently
on extracellular N. caninum tachyzoites and inhibited host cell
invasion. Additional pretreatment of DB745 prior to invasion
(30 min to 2 h) did not further decrease tachyzoite numbers, indi-
cating that the drug exerted its action swiftly. Moreover, it was
found that the parasite survival was signiﬁcantly impaired
(approximately 50% reduction) after only 30 min of extracellular
incubation in DB745-free medium, meaning that the mere extra-
cellular existence of N. caninum tachyzoites must already have
had a harmful effect on parasite infectivity.
3.3. DB745-treatment of HFF monolayers prior to infection with N.
caninum tachyzoites inhibited parasite proliferation
In order to investigate potential host cell-related effects against
parasite proliferation in vitro, HFF monolayers were incubated over
night with 1 lM DB745, were thoroughly washed with fresh med-
ium, and subsequently infected with N. caninum-beta-Gal tachyzo-
ites. After 1 h, medium was changed and subsequently cultures
were maintained either in the absence or presence of 1 lM
DB745. The pre-treatment of HFF monolayers resulted in signiﬁ-
cantly reduced (approximately 60%) parasite proliferation in vitro
even when subsequent culture during 3 days was carried out in
the absence of the drug (Fig. 2B). This suggested that the host cells
participated in the uptake or distribution of the compound in vitro.
Moreover, additional treatment of the infected cells, starting 1 h
after invasion, resulted in a cumulative inhibitory effect. Thus,
DB745 treatment of HFF monolayers prior to infection severely
inhibited intracellular proliferation of N. caninum tachyzoites.
Fig. 1. Dose–response applying DB745 and DB75 (as a negative control) for N. caninum and HFF monolayers. (A) Proliferation of transgenic N. caninum tachyzoites expressing
beta-galactosidase in the presence of different concentrations of DB745 was monitored by addition of chlorophenol red-b-D-galactopyranoside and measuring the absorption
shift at 570 nm. DB75 (furamidine) was included as a negative control. (B) The impact of different concentrations of DB745 on metabolic activity of HFF was measured by
Alamar blue assay. Figures show the results of one out of three independent experiments with virtually identical outcome. Error bars represent standard deviations. (C)
Comparison of DB745 and DB750 with regard to structure and calculated LogP values (cLogP). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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The potential of two isolates of N. caninum, Nc-1 and Nc-Liv, to
adapt to DB745 treatment was explored by slowly adapting them
to increasing drug concentrations. HFF monolayers grown in T25
tissue culture ﬂasks and infected with 104 Nc-1 or Nc-Liv tachyzo-
ites were initially subjected to 0.02 lM DB745, and the concentra-
tion was increased stepwise by 0.02 lM, typically every 3–8 days if
not indicated otherwise (see Table 1). For Nc-1 tachyzoites, DB745
concentrations could be stepwise increased up to 0.30 lM until
day 69. Proliferation stopped at this time point, and cultures were
maintained at the same drug concentration until day 86, since no
parasites could be detected anymore by light microscopy. Further
maintenance of the cultures was done in medium without
DB745, and recurrence of Nc-1 tachyzoites was noted between
days 108 and 111. In contrast, Nc-Liv tachyzoites appeared to exhi-
bit a lower adaptation potential compared to Nc-1, in that the
DB745 concentration could be increased only to 0.22 lM until
day 56, when proliferation ceased. Cultures were then further
maintained in 0.22 lM DB745 for 13 days, and subsequently in
medium without drug until day 111, but tachyzoites remainednon-detectable by light microscopy. This indicated that DB745
acted parasiticidal for Nc-Liv, but not for Nc-1 tachyzoites in vitro.
3.5. Effects of DB745 on the ultrastructure of N. caninum tachyzoites
The effects of DB745 on N. caninum tachyzoites were visualized
by TEM, through examination of specimens ﬁxed at 24, 48 and 72 h
post-treatment. In Fig. 3A and B, untreated tachyzoites are de-
picted, exhibiting a normal ultrastructure. The parasites are located
within a parasitophorous vacuole and surrounded by a parasitoph-
orous vacuole membrane. The hallmarks of apicomplexan parasites
such as the typical secretory organelles (rhoptries, micronemes
and dense granules) were clearly visible, as well as the conoid in
some instances (Fig. 3B). In cultures treated for 24 h with 1 lM
DB745, distinct ultrastructural alterations were visible. The cyto-
plasm of the parasites exhibited increased numbers of vacuoles,
some seemingly empty, others ﬁlled with membranous or electron
dense material of unknown origin (Fig. 3C and D). Clear alterations
were also noted within the nuclear membrane, the integrity of
which was altered in the drug-treated parasites compared to the
untreated specimens as it appeared partially separated. In addition,
Fig. 2. Effects of DB745 treatment of extracellular N. caninum tachyzoites and
pretreatments of HFF monolayers with DB745 on host cell invasion and intracel-
lular proliferation of N. caninum. (A) Extracellular N. caninum tachyzoites were pre-
incubated in the presence or absence of 1 lM DB745 for different durations, were
then allowed to invade HFF monolayers in the presence of the drug, and the ability
to proliferate in the absence of DB745 was investigated by beta-galactosidase
activity. Parasite proliferation was signiﬁcantly inhibited in all DB745 pre-treated
parasite samples. Signiﬁcance of P < 0.01 is designated as ⁄⁄⁄, P < 0.05 is written as ⁄.
(B) HFF monolayers grown to conﬂuency were incubated with 1 lM of DB745 over
night and subsequently infected with puriﬁed N. caninum tachyzoites of the Nc1
strain. Signiﬁcance: P < 0.05 is marked with ⁄, P < 0.01 is designated ⁄⁄⁄. The ability
to proliferate in the absence or presence of DB745 was investigated by beta-
galactosidase activity.
Table 1
Tachyzoites of the Nc-1 isolate, but not Nc-Liv tachyzoites, can adapt to stepwise
increasing concentrations of DB745. N. caninum Nc-1 and Nc-Liv were inoculated into
T25 tissue culture ﬂasks containing conﬂuent HFF monolayers, and cultured initially
in the presence of 0.02 lM DB745. At indicated time points the medium was replaced
with new medium containing either slightly elevated concentrations (+0.02 lM) of
DB745, or (at the later time points) medium was replaced containing the drug
concentration unchanged as indicated. Every 6–10 days cultures were trypsinized and
seeded onto fresh HFF monolayers.
Timepoints of treatment (days) Nc-1 DB745 (lM) N-Liv DB745 (lM)
0 0.02 0.02
3 0.02 0.02
7 0.04 0.04
10 0.04 0.04
14 0.06 0.06
17 0.06 0.06
21 0.08 0.08
24 0.08 0.08
27 0.10 0.10
31 0.12 0.12
35 0.14 0.14
38 0.14 0.14
42 0.16 0.16
45 0.18 0.18
48 0.18 0.18
52 0.20 0.20
56 0.22 0.22
59 0.24 0.22
63 0.26 0.22
66 0.28 0.22
69 0.30 0.22
73 0.30 Medium
76 0.30 Medium
80 0.30 Medium
83 0.30 Medium
86 Medium Medium
90 Medium Medium
93 Medium Medium
97 Medium Medium
101 Medium Medium
104 Medium Medium
108 Mediuma Medium
111 Mediuma Medium
a indicates recurrence of proliferation of Nc-1 tachyzoites between days 108 and
111.
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At 72 h of treatment, alterations became more evident and more
diverse (Fig. 4). On one hand, still viable intracellular tachyzoites
could be observed, with increased numbers of cytoplasmic vacu-
oles. These parasites were often in close contact in a way that
the cell membranes of two tachyzoites appeared to be fused to-
gether (Fig. 4A–C). Higher magniﬁcation views showed that para-
sites were clearly separated by two distinct inner membranes,
but held together by the outer plasmalemma, or alternatively,
the inner membrane was interrupted and ending blindly in the
cytoplasm (Fig. 4B and C). In many instances, extracellular tach-
yzoites were noted, which exhibited a completely altered and vac-
uolized cytoplasm, often with fragmented nuclear material, but
still an intact plasma membrane. Also intracellular parasitophor-
ous vacuoles with a clearly delineated parasitophorous vacuolemembrane and non-viable and structurally severely altered tach-
yzoites were found, ﬁlled with membranous vacuoles and electron
dense material of unknown origin.
The interference in the nucleor integrity in DB745-treated tach-
yzoites was further evaluated using a semiquantitative approach.
By random inspection of TEM micrographs of 100 treated and un-
treated tachyzoites we detected severe alterations or even lack of
nucleoli in 85% of all cells, while only 30% of all nuclei were devoid
of a nucleolus in non-treated tachyzoites.3.6. In vivo activity of DB745 in Balb/c mice experimentally infected
with N. caninum Nc-1 tachyzoites
Two types of experiment were performed. In experiment 1,
DB745 treatment by intraperitoneal injection (2 mg/kg/day) was
initiated 3 days prior to infection and was repeated daily for
14 days post-infection in order to give the drug the best chance
to act. The diamidine DB750 (2 mg/kg/day; (Debache et al.,
2011)) was included here for comparison. The results are summa-
rized in Table 2. In the placebo group treated with the solvent only,
3 out of 10 mice succumbed to disease between days 8 and 10
post-infection, and no fatalities were recorded in the two groups
receiving DB745 and DB750, respectively. There was no signiﬁcant
reduction of the weight of the mice during the treatment period in
any of the drug-treated groups, while in the group receiving
A B
C D
Fig. 3. TEM of N. caninum tachyzoites grown in HFF and visualization of effects after 24 h of DB745 treatment. (A) and (B) represent images of control cultures at 48 h post-
infection. Tachyzoites are located intracellular, within a parasitophorous vacuole. Rhoptries (Rop), micronemes (mic) and dense granules (dg) are visibile. Also visible in (B) is
the conoid (con) at the anterior part of the cells. Many nuclei contain an electron-dense nucleolus (ns). Note the intact nuclear membrane (white arrows). (C) and (D)
represent images of tachyzoites after treatment with 1 lMDB745 for 24 h. Separated nuclear membrane layers are pointed out with black arrows. v = vacuoles, partially ﬁlled
with membranous and/or electron-dense material of unknown origin. Bar in (A) = 1 lm; (B) = 0.28 lm; (C) = 0.45 lm; (D) = 0.33 lm.
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signiﬁcantly (P < 0.05). Assessments of cerebral parasite loads by
real time PCR in all three groups (Fig. 5A) demonstrated an appar-
ent reduction in tachyzoite numbers in the two drug-treated
groups, however, only the values for DB750 (P < 0.05) were statis-
tically signiﬁcant, while those for DB745 were not (P > 0.05). In
terms of serological responses to infection, there were no signiﬁ-
cant differences in IgG levels directed against crude N. caninum
antigen between placebo and treatment groups in sera taken at
the time of necroscopy (data not shown).
In experiment 2, DB745 treatmentswere initiated at day 14 post-
infection, thus at a time point at which N. caninum tachyzoites hadalready reached the CNS (Alaeddine et al., 2005; Collantes-Fernan-
dez et al., 2006), and were subsequently performed daily for a per-
iod of 2 weeks (see Table 2). Dosages were 2.5 mg/kg/day and
7.5 mg/kg/day. A placebo group treatedwith CMC only, and another
control group comprised of uninfectedmice treated with the higher
dosage of DB745 were included. None of the groups experienced
signiﬁcant weight loss during the entire treatment period. 5 out of
8 mice (62%) in the placebo group experienced severe signs of cere-
bral neosporosis such as walking disorders, head tilting and rufﬂed
coat, and had to be euthanized between days 13 and 26 post-infec-
tion. In the two groups receiving DB745, 2 out of 10 (20%) and 3 out
of 9mice (33%) exhibited clinical symptoms ofN. caninum infection,
AB
C
D E
Fig. 4. TEM of N. caninum tachyzoites after 72 h of DB745 treatment. (A) Low magniﬁcation view of a parasitophorous vacuole membrane with tachyzoites still fused
together. Tachyzoites show increased vacuolization (v) and cytoplasmic lipid droplets (ld). (B) Higher magniﬁcation view of the framed portion designated B in (A) showing
parasites that are clearly separated by two distinct inner membranes (im), but held together by the outer plasma membrane (om). (C) shows the framed portion on the left
hand side designated C in (A) at higher magniﬁcation. Note the blind ending of the inner membrane of the upper tachyzoite (white arrow). Black arrows show the contact sites
with the outer membrane fusing the parasites together. (D) Extracellular tachyzoite remnants (tachy) with distorted cytoplasm. (E) Intracellular and severely damaged
tachyzoites with a clearly delineated parasitophorous vacuole membrane (pvm). Parasites are ﬁlled with membranous vacuoles and electron dense material, black arrows
point towards irregular membrane structures. Bar in (A) = 0.5 lm; (B) = 0.12 lm; (C) = 0.12 lm; (D) = 1 lm; (E) = 0.4 lm.
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fected mice treated with the higher dosage of DB745 (7.5 mg/kg/
day; Table 2). Quantitative real time PCR of cerebral tissues
(Fig. 5B) showed that DB745 treatments reduced the overall number
of tachyzoites in the brain, with the treatment at 7.5 mg DB745/kg/
day providing increased efﬁcacy (P < 0.05) compared to 2.5 mg/kg/
day. The parasite load in the corresponding lung tissue samples also
appeared decreased, but values were not signiﬁcantly different
(Fig. 5C). Assessment of IgG levels against N. caninum antigens in
sera taken at necroscopy did not exhibit any differences in the treat-
ment groups (data not shown).
4. Discussion
Neosporosis is an infectious problem affecting cattle and other
intermediate hosts worldwide. There is no efﬁcient vaccine avail-
able to date that provides complete protection against infection,
and no effective means of treatment have been developed so far
(Dubey and Schares, 2011). The aim of this study was to compare
the in vitro efﬁcacy of a panel of 41 di-cationic pentamidine deriv-
atives against N. caninum tachyzoites, and to characterize potential
compounds of interest. This resulted in the identiﬁcation of DB745,
a di-cationic arylimidamide compound that efﬁciently inhibited
both host cell invasion and intracellular proliferation of N. caninum
tachyzoites. DB745 acted parasiticidal on the Nc-Liv isolate of N.
caninum, but only parasitostatic on the Nc1 isolate. Although the
potency of DB745 against N. caninum tachyzoites in vitro wassimilar to DB750 (a previously described and closely related com-
pound; (Debache et al., 2011; Leepin et al., 2008)), its efﬁcacy
in vivo in experimentally infected mice was slightly lower.
Di-cationic pentamidine derivatives, especially arylimidamides
and related compounds, have been shown to exhibit broad-spec-
trum anti-parasitic properties in vitro and partially also in vivo,
most notably against intracellular pathogens such as T. cruzi, N.
caninum, B. besnoiti, L. donovani, and T. gondii (Batista et al.,
2010a,b; Cortes et al., 2011; Kropf et al., 2012; Leepin et al., 2008;
Silva et al., 2007a,b; Stephens et al., 2003). The di-cationic mole-
cules used here have been designed to exhibit improved pharmaco-
kinetic properties by including aryl groups on one of the amidine
nitrogen atoms (Wang et al., 2010). The fact that DB745 was iden-
tiﬁed as a potentially interesting candidate due to its low IC50
(80 nM) and favorable selective toxicity (see Fig. 1) was not surpris-
ing. This compound has been previously shown to be highly active
against two strains of T. gondii tachyzoites (Rh andMe49, exhibiting
high and low virulence, respectively), with an IC50 of 0.03 lM in
3 days growth assays (Kropf et al., 2012). In addition, DB745 repre-
sents a lead compound for the treatment of visceral leishmaniasis
caused by L. donovani, and exhibits an in vitro IC50 against intracel-
lular L. donovani of 0.018 ± 0.007 lM (Wang et al., 2010).
Previous studies (Debache et al., 2011; Leepin et al., 2008) had
shown that DB750, a compound closely related to DB745, but with
hydroxyl groups on the phenyl rings instead of ethoxy groups, was
active against N. caninum tachyzoites in vitro (IC50 = 0.16 lM) and
in vivo in experimentally infected mice. The substitution of the
Table 2
Summary of in vivo experiments with respect to experimental groups, numbers of mice with disease symptoms, time of death and mean animal weights during treatments with
DB745. Note that in Experiment 1 (treatment starting prior to infection) the diamidine DB750 was included as a positive control.
Experimental groups & dosage (per kg/day) nb Symptomatic mice Time of death (days p-i.) Mean weight (g) at
Beginning End
Exp. 1 Placebo 10 3 8/8/10 20.14 ± 0.5 17.83 ± 0.78a
2 mg DB745 10 – – 19.96 ± 0.52 19.4 ± 0.96
2 mg DB750 10 – – 20.13 ± 0.72 19.81 ± 0.74
Exp. 2 Placebo 8 5 13/16/26/26/26 19.87 ± 0.64 18.9 ± 0.72
2.5 mg DB745 10 2b 16/18 19.96 ± 0.50 19.25 ± 1.07
7.5 mg DB745 9 3 15/20/26 19.55 ± 1.01 19.16 ± 0.98
7.5 mg DB745 non inf. 9 – – 19.88 ± 0.70 19.85 ± 0.93
a Indicates signiﬁcant weight loss in the placebo group (P < 0.05).
b Indicates that the percentage of surviving mice in the DB745 treatment group was signiﬁcantly higher than in the placebo group (P < 0.05).
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DB745 possibly resulted in increased metabolic resistance, also
rendering DB745 more lipophilic (logP at pH 7.4 = 3.82 (Wang
et al., 2010)), and possibly provided superior membrane perme-
ability. This in turn could increase the chances of the drug passing
through several layers of membrane (host cell, parasitophorous
vacuole, parasite cell membrane, target organelle) in order to exert
its anti-parasitic activity. While DB750 only inhibited intracellular
proliferation of N. caninum tachyzoites in vitro and did not exert
any toxicity against extracellular tachyzoites (Leepin et al., 2008),
DB745 had an impact on both host cell invasion (extracellular par-
asites) and intracellular proliferation (see Fig. 2). The observed
impairment of infectivity upon N. caninum tachyzoites incubated
extracellularly in the absence of DB745 is in agreement with earlier
ﬁndings indicating that N. caninum rapidly lost the capacity to in-
vade host cells upon extracellular maintenance (Hemphill et al.,
1996; Naguleswaran et al., 2003). DB745 exerted its action swiftly,
which is in agreement with recent investigations on the action of
arylimidamides against T. cruzi, the causative agent of Chagas dis-
ease (Da Silva et al., 2011).
In analogy to DB750, pre-incubation of HFF monolayers with
DB745 also resulted in a substantial inhibition of N. caninum tach-
yzoite proliferation, even when infected cells were subsequently
maintained in the absence of the compound. An additional inhibi-
tory effect was noted when the drug was again added to infected
cells following pretreatment of HFF. Similar results were obtained
in experiments employing DB750 on T. gondii (Kropf et al., 2012).
This supported the notion that compounds such as DB750 and
DB745 were likely to be efﬁciently taken up by host cells, and then
subsequently retained in the host cell cytoplasm, where they con-
tinued to exert anti-parasitic activity for extended periods of time.
This argues for the presence of an active transport mechanism for
drug uptake. For instance, a human organic cation transporter
which uses pentamidine and furamidine as substrates identiﬁed
by Ming et al. (2008) could mediate DB750 and DB745 uptake into
HFF. However, furamidine (DB75) does not exhibit in vitro activity
against N. caninum tachyzoites (see Fig. 1). Clearly, the current evi-
dence does not allow deﬁnitive conclusions, and the possibility of
passive uptake of these compounds through biological membranes
also cannot be discarded. Further work is required to clarify this
point.
The two isolates differed in their ability to adapt to DB745 treat-
ment, when exposure to the drug was done by slow and stepwise
increase of drug concentration. Nc-Liv was able to cope with a
maximum concentration of 0.20 lM and subsequently ceased pro-
liferation even in the absence of the drug, indicating parasiticidal
activity of DB745. In contrast Nc-1 tachyzoites kept proliferating
up to a concentration of 0.33 lM, then underwent a phase of no
or only little growth, and after maintenance in medium without
compound resumed proliferation towards the end of the experi-ment. Thus, the particular conditions in this experiment were obvi-
ously more suitable to ensure survival of Nc-1 tachyzoites. This
conﬁrmed earlier studies that demonstrated distinct genetic and
biological differences of different N. caninum isolates (Atkinson
et al., 1999; Schock et al., 2001). The ability to, at least partially,
adapt to increased drug concentrations during in vitro culture has
also been demonstrated for T. gondii tachyzoites, which readily
adapted to 1.2 lM DB750 within 5–6 days of in vitro culture. This
represented a 10 times higher concentration than the correspond-
ing IC50 (=0.13 lM). In addition, T. gondii tachyzoites also readily
adapted to increased concentrations (up to 0.46 lM) of DB745
(Kropf et al., 2012). Thus, N. caninum does not seem to exhibit
the potential for reacting to adverse physiological conditions to
the same extent as Toxoplasma, although the two species are clo-
sely related. The underlining molecular mechanisms are not
known, but the lower potential of Neospora to react to environ-
mental changes could be one factor that limited the range of poten-
tial intermediate hosts of this parasite in comparison to T. gondii
(Hemphill et al., 2006; Dubey et al., 2007). It has been shown that
T. gondii exhibits an outstandingly high degree of ﬂexibility on the
transcriptional and translational level (Bougdour et al., 2010), but
not much is known on the regulation of gene expression in N.
caninum.
The mode of action of di-cationic pentamidine derivatives is not
yet completely resolved. The current view suggests that these com-
pounds bind to AT-rich sites in the DNA minor groove, and thus in-
hibit transcription or the interaction with DNA-binding enzymes
such as topoisomerases or nucleases (Wilson et al., 2008). This indi-
cates that these compounds could inﬂuence gene expression, and
thus many diverse cellular functions could be affected. In addition,
other cellular functions could be affected directly or indirectly. In
kinetoplastids such as T. cruzi, treatment with diamidines resulted
in mitochondrial swelling (Batista et al., 2010b). TEM was carried
out in this study to investigate the ultrastructural differences be-
tween DB745-treated and non-treatedN. caninum tachyzoites. Dur-
ing the course of drug treatment, rather unspeciﬁc alterations were
observed in DB745-treated tachyzoites such as increased vacuoliza-
tion starting already after 24 h. At 72 h, increased numbers of either
extracellularly located and obviously distorted tachyzoiteswere ob-
served, or intracellular tachyzoites exhibiting severely aberrant and
compartmentalized cytoplasmic organization ﬁlled with vesicles,
membrane stacks, electron dense granules and lipid droplets.
Roughly similar ﬁndings were obtained in N. caninum tachyzoites
treated with toltrazuril and ponazuril (Darius et al., 2004), thiazo-
lide compounds (Esposito et al., 2005), andwithmiltefosine-treated
N. caninum tachyzoites (Debache and Hemphill, 2012). However,
two additional and possibly more speciﬁc alterations were ob-
served. First, at 24 h (Fig. 3C and D), the nuclear membrane of many
tachyzoites exhibited a loosened appearance, indicating separation
of the double-layered nuclear membrane. In addition, in many
Fig. 5. Effects of DB745 treatment in experimentally infected mice with respect to
parasite load in the brain and lungs. (A) Cerebral parasite burden in mice receiving
treatments starting 3 days prior to infection with 2  106 N. caninum tachyzoites.
Mice were treated either by intraperitoneal application of DB745 or DB750, both at
2 mg/kg/day for a period of 14 days. The parasite burden was assessed by Neospora
real time PCR. Note the signiﬁcantly reduced infection load in the group treated by
intraperitoneal application of DB750. ⁄ indicates signiﬁcant reductions in parasite
numbers (P < 0.05). (B) Cerebral parasite burden in brain tissue of mice receiving
intraperitoneal treatments with DB745 (2.5 mg/kg/day or 7.5 mg/kg/day) starting
14 days after infection with 2  106 N. caninum tachyzoites. Note the signiﬁcantly
reduced parasite load (⁄P < 0.05) in the group treated with 7.5 mg/kg/day. (C)
Parasite burden in the lungs, experimental groups are identical to (B). Note the
apparent reduction, (although not signiﬁcant) as assessed by real time PCR.
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This suggested that DB745 could interfere in themaintenance of the
nuclear membrane integrity, possibly interfere in lipid metabolism,
and/or in transcriptional activity of these parasites. Secondly, many
intracellular tachyzoites visualized at 72 h of DB745 treatmentwere
found fused together (Fig. 4A–C). Closer inspection of the contactsites at higher magniﬁcation revealed that these were probably
tachyzoites caught in the process of endodyogeny, with the inner
membrane layer surrounding both daughter cells and the inner
membrane layer either fully present (Fig. 4B) or partially inter-
rupted (Fig. 4C). Similar aberrant membrane structures were found
on non-viable intracellular tachyzoites still located within a parasi-
tophorous vacuole (Fig. 4E). Thus, these observations also indicated
that DB745 could potentially interfere in the formation/metabolism
of membranous structures within these parasites.
These promising in vitro activities lead to this study, which was
performed in order to assess the efﬁcacy of DB745 in mice exper-
imentally infected with N. caninum Nc-1 tachyzoites. In experi-
ment 1, the drug was given the best chance to act, and none of
the mice in the DB745 treatment group exhibited signs of disease,
similar to another experimental group that was treated with
DB750 (Table 2; Fig. 5A; Debache et al., 2011). In experiment 2,
treatment at two dosages was initiated after parasites had crossed
the blood–brain border and invaded the CNS (Alaeddine et al.,
2005; Collantes-Fernandez et al., 2006), and application of
(7.5 mg/kg/day) resulted in beneﬁtial outcome in 6 out of 9 mice,
while only 3 out of 8 mice in the placebo group survived. In addi-
tion, DB745 treatment resulted in a signiﬁcantly reduced cerebral
parasite burden (Fig. 5B). This indicated that DB745, similar to
DB750, most likely crossed the blood–brain barrier and exerted
its action also within cerebral tissues. A similar reduction of para-
site numbers due to DB745 treatment was also noted in lung tis-
sues, however, compared to the placebo control group, these
values were not signiﬁcantly different (Fig. 5C).
Thus, these initial in vivo results are promising, and point out
the therapeutic potential of the arylimidamide DB745 and related
compounds. Wang et al. (2010) described the pharmacokinetics of
the arylimidamides DB745 and DB766 in mice. DB745 exhibited
improved oral bioavailability and pharmacokinetics compared to
di-cationic arylimidamides such as DB750. DB766, which is one
of the compounds originally identiﬁed by Leepin et al. (2008),
although with a slightly higher IC50 (0.30 lM) compared to
DB750 (0.23 lM) against N. caninum in vitro but with a lower tox-
icity proﬁle, will also be of great interest to be evaluated for the
treatment of N. caninum infection. However, these results provide
evidence on the efﬁcacy of DB745 against tachyzoites and conse-
quently the acute phase of neosporosis. The most interesting ﬁnd-
ings would be to demonstrate effects against cyst-forming
bradyzoites, which are metabolically different and are responsible
for the chronic phase of infection. Only few reports have been pub-
lished so far on the production of N. caninum tissue cysts in mice,
such as in inbred CBA/Ca mice and outbred mice (McGuire et al.,
1997; Rettigner et al., 2004). More recently, Neospora tissue cyst
production, marked by positive staining with an antibody directed
against the Toxoplasma bradyzoite antigen BAG5, has also been
demonstrated in an experimentally infected carnivorous marsu-
pial, the fat-tailed dunnart Sminthopsis crassicaudata (King et al.,
2011). It is also very likely that N. caninum tissue cysts are not nec-
essarily formed only in the CNS but also in other locations such as
in muscle tissue (Peters et al., 2001; King et al., 2011), and this
should be taken into account in future studies. .
In conclusion, we have demonstrated different aspects of the
in vitro and in vivo efﬁcacy of the arylimidamide DB745, showing
that this drug exhibits the potential of a lead compound for further
investigations on therapeutical approaches to neosporosis, and
other diseases caused by cyst-forming apicomplexans that invade
the CNS. The class of di-cationic compounds as a whole should
be further exploited in order to identify potentially interesting can-
didate drugs. From the practical point of view on neosporosis in
cattle, treatment of congenitally infected calves right after birth
could potentially give rise to pathogen-free offspring (Härdi
et al., 2006), provided an effective compound can be identiﬁed.
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